Dobutamine pharmacokinetics in severe heart failure

Area of Science:

• Pharmacology
• Cardiology
• Clinical Pharmacy

Background:

• Severe cardiac failure presents complex physiological challenges.
• Understanding drug pharmacokinetics is crucial for effective treatment.
• Dobutamine is a commonly used inotrope in cardiac conditions.

Purpose of the Study:

• To investigate the pharmacokinetics of dobutamine in patients with severe cardiac failure.
• To determine key pharmacokinetic parameters like clearance, half-life, and volume of distribution.
• To explore potential relationships between dobutamine distribution and patient factors such as edema.

Main Methods:

• Dobutamine was administered via constant intravenous infusion at escalating rates (2.5–10.0 µg/kg/min).
• Plasma levels were measured at steady-state during infusion and after termination.
• Pharmacokinetic parameters were calculated using plasma concentration-time data.

Main Results:

• Steady-state plasma dobutamine levels increased proportionally with infusion rates, suggesting no disposition saturation.
• Average total body clearance was 2.35 ± 1.01 L/min/m².
• Elimination half-life was 2.37 ± 0.7 min, and volume of distribution was 0.202 ± 0.084 L/kg.

Conclusions:

• Dobutamine exhibits linear pharmacokinetics in severe cardiac failure patients within the studied dose range.
• The drug is rapidly eliminated, with a short half-life.
• The volume of distribution may be influenced by the presence and extent of edema in these patients.